President Obama recently announced that the US government will invest $215 million in research funding intended to drive patient-powered research and further the cause of personalized medicine. In the announcement it was stated that, “Through collaborative public and private efforts, the Precision Medicine Initiative will leverage advances in genomics, emerging methods for managing and analyzing large data sets while protecting privacy, and health information technology to accelerate biomedical discoveries.”
We are at the forefront of a new medical research paradigm that is focused on the individual rather than the collective. This approach to research and patient care will form the basis of the BluePrint Global Health Foundation’s strategy to combat the current challenge of unmet medical needs.
Two of BluePrint Global Health Foundation’s members, Matt Nunez and Patrick Lilley, each run companies that are making large strides towards keeping the personalized medicine promise. Patrick Lilley is the CEO of Emerald Logic, a leader in the field of computational biology. This company has proven to solve some of the largest problems with the immense data generated by clinical trials by identifying and defining non-linear relationships and effects of biological factors that lead to drug development success.
Matt Nunez, the founder of BluePrint Global Health Foundation, is the founder and CEO of BluePrint Bio, a company that is discovering, validating, protecting, publishing and commercializing new solutions for the global health market. In many cases, a discovery that may not warrant for-profit commercialization but can solve an unmet global medical need can and will be developed through our nonprofit foundation.
It is gratifying to see that the administration is providing resources and further credibility to the model of personalized medicine. We fully intend to be very active in this effort.